This content is only available within our institutional offering.

06 Sep 2017
LIBERUM: Shield Therapeutics* - US composition patent granted to 2035; further support for long duration of cashflows

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
LIBERUM: Shield Therapeutics* - US composition patent granted to 2035; further support for long duration of cashflows
Shield Therapeutics Plc (STX:LON) | 2.8 0 0.0% | Mkt Cap: 29.7m
- Published:
06 Sep 2017 -
Author:
Roger Franklin | Graham Doyle -
Pages:
2 -